MedPath

Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers

Not Applicable
Completed
Conditions
Healthy
Registration Number
NCT00958399
Lead Sponsor
University of Minnesota
Brief Summary

Research suggests dietary fiber may play a role in weight management, and fiber consumption is inversely associated with body weight, body fat, and BMI in cross-sectional studies. These effects may be mediated by increased satiety, reduced food intake, or changes in blood levels of glucose, insulin, and gut hormones.

The purpose of this study is to determine the satiety, glycemic, hormonal, and gastrointestinal responses of novel fiber supplements.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • healthy men and women
  • age 18-60 years
  • non-smoking
  • not taking medication
  • non-dieting (weight stable in prior 3 months)
  • BMI 18-27
  • English literacy
  • ability to give blood
Exclusion Criteria
  • do not regularly consume breakfast
  • food allergies to ingredients found in study products
  • dislike for muffins, fiber bars, or hot cereal
  • BMI <18 or >27
  • diagnosed cardiovascular, renal, or hepatic disease
  • diabetes mellitus (fasting blood sugar >126 mg/dl)
  • cancer in previous 5 years (except basal cell carcinoma of the skin)
  • any gastrointestinal disease or condition
  • recent bacterial infection (< 3 months)
  • recent or concurrent participation in an intervention research study
  • history of drug or alcohol abuse in prior 6 months
  • use of lipid-lowering, anti-hypertensive, or anti-inflammatory steroid medication
  • restrained eaters
  • vegetarians
  • people who eat more than approximately 15 grams of fiber per day
  • women who are pregnant or lactating
  • women with irregular menstrual cycles

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Satiety0, 15, 30, 45, 60, 90, 120, 180, 215 minutes postprandially
Secondary Outcome Measures
NameTimeMethod
ad libitum food intake180 minutes postprandially and over 24 hours
Ghrelin, polypeptide YY (PYY), and glucagon-like peptide-1 (GLP-1) response0, 30, 60 minutes postprandially
Gastrointestinal tolerance and fecal chemistryfollowing 7 days of treatment
Glucose/Insulin Response0, 15, 30, 45, 60, 90, 120, 180 minutes postprandially

Trial Locations

Locations (1)

University of Minnesota - General Clinical Research Center

🇺🇸

Minneapolis, Minnesota, United States

University of Minnesota - General Clinical Research Center
🇺🇸Minneapolis, Minnesota, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.